Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Longeveron is a clinical-stage biotechnology company focused on developing regenerative medicines for life-threatening and chronic aging-related conditions. The company's core technology is Lomecel-B, an allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy designed to promote tissue repair and reduce inflammation. Longeveron is currently advancing clinical programs in Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease, and Aging Frailty. Founded by Dr. Joshua M. Hare, a pioneer in stem cell research, the company is headquartered in Miami and is publicly traded on the NASDAQ. The company leverages its proprietary manufacturing process to produce high-quality cell therapies for its diverse clinical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Joshua M Hare.